[go: up one dir, main page]

PT1622912E - Antagonistas 2-alcinil- e 2-alcenilpirazolo-[4,3-b]-1,2,4- triazolo-[1,5-c]-pirimidina do receptor a2a da adenosina - Google Patents

Antagonistas 2-alcinil- e 2-alcenilpirazolo-[4,3-b]-1,2,4- triazolo-[1,5-c]-pirimidina do receptor a2a da adenosina Download PDF

Info

Publication number
PT1622912E
PT1622912E PT04760128T PT04760128T PT1622912E PT 1622912 E PT1622912 E PT 1622912E PT 04760128 T PT04760128 T PT 04760128T PT 04760128 T PT04760128 T PT 04760128T PT 1622912 E PT1622912 E PT 1622912E
Authority
PT
Portugal
Prior art keywords
triazolo
pyrazolo
alkynyl
alkenyl
receptor antagonists
Prior art date
Application number
PT04760128T
Other languages
English (en)
Inventor
Bernard R Neustadt
Craig D Boyle
Samuel Chackalamannil
Jinsong Hao
Hong Liu
Unmesh G Shah
Andrew Stamford
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of PT1622912E publication Critical patent/PT1622912E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PT04760128T 2003-04-23 2004-04-21 Antagonistas 2-alcinil- e 2-alcenilpirazolo-[4,3-b]-1,2,4- triazolo-[1,5-c]-pirimidina do receptor a2a da adenosina PT1622912E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46484003P 2003-04-23 2003-04-23

Publications (1)

Publication Number Publication Date
PT1622912E true PT1622912E (pt) 2009-08-17

Family

ID=33310963

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04760128T PT1622912E (pt) 2003-04-23 2004-04-21 Antagonistas 2-alcinil- e 2-alcenilpirazolo-[4,3-b]-1,2,4- triazolo-[1,5-c]-pirimidina do receptor a2a da adenosina

Country Status (31)

Country Link
US (2) US6897217B2 (pt)
EP (1) EP1622912B1 (pt)
JP (2) JP4527712B2 (pt)
KR (1) KR100831107B1 (pt)
CN (1) CN100503609C (pt)
AR (1) AR044041A1 (pt)
AT (1) ATE432282T1 (pt)
AU (1) AU2004233334B2 (pt)
BR (1) BRPI0409787B8 (pt)
CA (1) CA2522813C (pt)
CL (1) CL2004000847A1 (pt)
CO (1) CO5700766A2 (pt)
CY (1) CY1109263T1 (pt)
DE (1) DE602004021250D1 (pt)
DK (1) DK1622912T3 (pt)
EC (1) ECSP056115A (pt)
ES (1) ES2326270T3 (pt)
HR (1) HRP20090394T1 (pt)
IL (1) IL171567A (pt)
MX (1) MXPA05011366A (pt)
MY (1) MY139344A (pt)
NO (1) NO332182B1 (pt)
NZ (1) NZ542823A (pt)
PE (1) PE20050141A1 (pt)
PL (2) PL378867A1 (pt)
PT (1) PT1622912E (pt)
RU (1) RU2373210C2 (pt)
SI (1) SI1622912T1 (pt)
TW (2) TWI375677B (pt)
WO (1) WO2004094431A2 (pt)
ZA (1) ZA200508489B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7313588B1 (en) * 2000-07-13 2007-12-25 Biap Systems, Inc. Locally executing software agent for retrieving remote content and method for creation and use of the agent
ATE453647T1 (de) * 2001-11-30 2010-01-15 Schering Corp Adenosin a2a rezeptor antagonisten
NZ540493A (en) * 2002-12-19 2008-04-30 Schering Corp Uses of adenosine A2a receptor antagonists
US20060128694A1 (en) * 2002-12-19 2006-06-15 Michael Grzelak Adenosine A2a receptor antagonists for the treatment of extra-pyramidal syndrome and other movement disorders
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists
US7709492B2 (en) * 2004-04-21 2010-05-04 Schering Corporation Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
EP2258372B8 (en) * 2005-06-07 2012-12-19 Kyowa Hakko Kirin Co., Ltd. A2A antagonists for use in the treatment of motor disorders
CA2622741A1 (en) 2005-09-19 2007-03-29 Schering Corporation 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
AR056080A1 (es) 2005-09-23 2007-09-19 Schering Corp 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine
ES2273599B1 (es) 2005-10-14 2008-06-01 Universidad De Barcelona Compuestos para el tratamiento de la fibrilacion auricular.
US7723343B2 (en) * 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
JP2011513417A (ja) * 2008-03-04 2011-04-28 シェーリング コーポレイション アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物
US8512594B2 (en) * 2008-08-25 2013-08-20 Air Products And Chemicals, Inc. Curing agent of N,N′-dimethyl-meta-xylylenediamine and multifunctional amin(s)
US8501997B2 (en) * 2008-08-25 2013-08-06 Air Products And Chemicals, Inc. Curing agent for low temperature cure applications
SG173757A1 (en) 2009-03-10 2011-09-29 Takeda Pharmaceutical Benzofuran derivatives
US8598343B2 (en) 2009-08-07 2013-12-03 Merck Sharp & Dohme Corp. Process for preparing a 2-alkynyl substituted 5-amino-pyrazolo-[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
CN104870421A (zh) * 2011-12-27 2015-08-26 比皮艾思药物研发有限公司 用于预防或治疗als的苯基氨基甲酸酯化合物
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
BR112015020998B1 (pt) * 2013-03-14 2022-10-18 Galapagos Nv Compostos e composições farmacêuticas dos mesmos para o tratamento de distúrbios inflamatórios
US11498923B2 (en) 2017-12-13 2022-11-15 Merck Sharp & Dohme Llc Substituted imidazo[1,2-c]quinazolines as A2A antagonists
US20230024108A1 (en) * 2019-07-17 2023-01-26 Teon Therapeutics, Inc. Adenosine a2a receptor antagonists
CN115160120B (zh) * 2022-08-02 2024-08-27 乐威医药（江苏）股份有限公司 一种多烷氧基芳香酮的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US785906A (en) * 1904-12-06 1905-03-28 Albert P Mcbride Casing packer and shoe for gas or oil wells.
MX16165A (es) * 1988-05-25 1994-02-28 Dow Chemical Co Alcoxi-1,2,4-triazolo[1,5-c]pirimidin-2-sulfonamidas, procedimiento para su preparacion e intermediarios.
IT1264901B1 (it) 1993-06-29 1996-10-17 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(15-c)pirimidine ad attivita' antagonista per il recettore a2 dell'adenosina
AU7237294A (en) 1993-07-27 1995-02-28 Kyowa Hakko Kogyo Co. Ltd. Remedy for parkinson's disease
IT1277392B1 (it) 1995-07-28 1997-11-10 Schering Plough S P A Analoghi eterociclici di 1,2,4-triazolo(1,5-c]pirimidine ad attivita' antagonista per il recettore a2a dell'adenosina
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
DE19826843A1 (de) * 1998-06-16 1999-12-23 Boehringer Ingelheim Pharma Neue Imidazotriazolopyrimidine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
MXPA02011625A (es) * 2000-05-26 2003-03-27 Schering Corp Antagonistas receptores de adenosina a2a.
GB0100624D0 (en) 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
JPWO2002062801A1 (ja) * 2001-02-05 2004-06-10 株式会社大塚製薬工場 トリアゾロキナゾリン及びピラゾロトリアゾロピリミジン誘導体、医薬組成物、アデノシンａ３受容体親和剤、眼圧低下剤、緑内障の予防及び治療のための製剤、並びに眼圧低下方法
AR037243A1 (es) 2001-10-15 2004-11-03 Schering Corp Antagonistas del receptor de adenosina a2a,a5-amino-imidazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]pirimidina, composiciones farmaceuticas y el uso de dichos compuestos para la preparacion de un medicamento
NZ540493A (en) * 2002-12-19 2008-04-30 Schering Corp Uses of adenosine A2a receptor antagonists
EP1622912B1 (en) * 2003-04-23 2009-05-27 Schering Corporation 2-alkynyl-and 2-alkenyl-pyrazolo- [4,3-e ] -1,2,4-triazolo- [1,5-c] -pyrimidine adenosine a2a receptor antagonists

Also Published As

Publication number Publication date
BRPI0409787B1 (pt) 2018-08-21
NZ542823A (en) 2009-03-31
HK1085466A1 (en) 2006-08-25
NO20055510D0 (no) 2005-11-22
JP2010059178A (ja) 2010-03-18
PE20050141A1 (es) 2005-04-01
KR100831107B1 (ko) 2008-05-20
DE602004021250D1 (de) 2009-07-09
DK1622912T3 (da) 2009-09-07
WO2004094431A3 (en) 2004-12-02
TW201144317A (en) 2011-12-16
TW200427689A (en) 2004-12-16
CA2522813A1 (en) 2004-11-04
CL2004000847A1 (es) 2005-03-11
MXPA05011366A (es) 2005-11-28
KR20060005379A (ko) 2006-01-17
ES2326270T3 (es) 2009-10-06
AR044041A1 (es) 2005-08-24
CN1777609A (zh) 2006-05-24
PL1622912T3 (pl) 2009-11-30
US20040220194A1 (en) 2004-11-04
NO20055510L (no) 2006-01-20
WO2004094431A2 (en) 2004-11-04
MY139344A (en) 2009-09-30
ZA200508489B (en) 2007-04-25
RU2373210C2 (ru) 2009-11-20
BRPI0409787B8 (pt) 2021-05-25
US20050222164A1 (en) 2005-10-06
RU2005136166A (ru) 2006-06-10
PL378867A1 (pl) 2006-05-29
CY1109263T1 (el) 2014-07-02
BRPI0409787A (pt) 2006-05-30
ATE432282T1 (de) 2009-06-15
EP1622912B1 (en) 2009-05-27
SI1622912T1 (sl) 2009-10-31
US7368449B2 (en) 2008-05-06
CN100503609C (zh) 2009-06-24
JP4527712B2 (ja) 2010-08-18
TWI375677B (en) 2012-11-01
JP2006523619A (ja) 2006-10-19
AU2004233334B2 (en) 2010-08-12
IL171567A (en) 2013-01-31
EP1622912A2 (en) 2006-02-08
US6897217B2 (en) 2005-05-24
NO332182B1 (no) 2012-07-23
HRP20090394T1 (hr) 2009-08-31
TWI355381B (en) 2012-01-01
CA2522813C (en) 2009-09-08
CO5700766A2 (es) 2006-11-30
ECSP056115A (es) 2006-03-01
AU2004233334A1 (en) 2004-11-04

Similar Documents

Publication Publication Date Title
IL178674A0 (en) PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS
IL160878A0 (en) Imidazo (4,3-e)-1,2,4-triazolo (1,5-c) pyrimidines as adenosine a2a receptor antagonists
PT1622912E (pt) Antagonistas 2-alcinil- e 2-alcenilpirazolo-[4,3-b]-1,2,4- triazolo-[1,5-c]-pirimidina do receptor a2a da adenosina
IL220174A0 (en) 5-AMINO - {PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE}-2-AND 7-SUBSTITUTED DERIVATIVES AS ADENOSINE A2A RECEPTOR INHIBITORS
IL158214A0 (en) 8-heteroaryl xanthine adenosine a2b receptor antagonists
TWI365879B (en) A2b adenosine receptor antagonists
IL161716A0 (en) ADENOSINE A2a RECEPTOR ANTAGONISTS
IL161572A0 (en) Adenosine a2a receptor antagonists
HUP0401925A3 (en) A2b adenosine receptor antagonists
EP1599482A4 (en) PYRAZOLO1,5-A PYRIMIDINE DERIVATIVES
IL178365A0 (en) Selective antagonists of a2a adenosine receptors
HUP0402324A3 (en) [1,2,4]triazolo[1,5-a]pyridine and [1,2,4]triazolo[1,5-c]pyrimidine derivatives as adenosine a2a receptor antagonists and pharmaceutical compositions containing them
ZA200708524B (en) Process for preparing pyrido[2,3-D]pyrimidin-7-one and 3,4-dihydropyrimido[4,5-D]pyrimidin-2(1H)-one derivatives
IL170680A0 (en) 8 - SUBSTITUTED - 6,7,8,9 -TETRAHYDROPYRIMIDO [1,2-a] PYRIMIDIN - 4 - ONE DERIVATIVES
ZA200507192B (en) Substituted 8-perfluoroalkyl-6,7,8,9-tetrahydropyrimido [1,2-A] pyrimidin-4-one derivatives
IL174771A0 (en) Pyrimidin-2-amine derivatives and their use as a2b adenosine receptor antagonists
PL377053A1 (pl) Związki 2-aminokarbonylo-chinoliny jako antagonisty receptora płytkowego difosforanu adenozyny
PL1678182T3 (pl) Sposób wytwarzania podstawionych 5-aminopirazolo[4,3-e]-1,2,4-triazolo-[1,5-c]pirymidyn
PL370565A1 (en) 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists
ZA200608778B (en) Pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
HK1118045A (en) 2-heteroaryl-pyrazolo-[4, 3-e]-1, 2, 4-triazolo-[1,5-c]-pyrimidine as adenosine a2a receptor antagonists
HK1062534A (en) Imidazo (4,3-e)-1,2,4-triazolo(1,5-c) pyrimidines as adenosine a2a receptor antagonists
TH0401001406A (th) 2-อัลไคนิล-และ 2-อัลคีนิล-ไพราโซโล-[4,3-e]-1,2,4-ไตรอะโซโล-[1,5-c]-ไพริมิดีน ที่เป็นแอนทาโกนิสท์ของตัวรับอะดีโนซีนA2a
HK1085202A (en) Triazolo[1,5-c]pyrimidines and pyrazolo[1,5-c]pyrimidines useful as a2a adenosine receptor antagonists
HK1085201A (en) Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosine receptor antagonists